Diabetes drugs may zap precancerous mouth lesions in new trial

NCT ID NCT05727761

Recruiting now Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of two diabetes drugs, pioglitazone and metformin, can shrink or improve precancerous patches in the mouth called oral leukoplakia. About 36 adults with high-risk lesions will take the pills twice daily for 12 weeks. The goal is to see if the treatment reduces the size and severity of the patches and lowers cell growth markers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ORAL LEUKOPLAKIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

oral mucosa leukoplakia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ORAL LEUKOPLAKIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

HealthPartners
RECRUITING

Saint Paul, Minnesota, 55130, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••